Obesity and headache: Part II - Potential mechanism and treatment considerations

Headache

Volumn 54, Issue 3, 2014, Pages 459-471

  Cindy Chai, Nu ^a   Bond, Dale S ^c   Moghekar, Abhay ^a   Scher, Ann I ^b   Peterlin, B Lee ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

body mass index; headache; migraine; obesity

Indexed keywords

ADIPOCYTOKINE; AMITRIPTYLINE; CANDESARTAN; CAPTOPRIL; CYPROHEPTADINE; DULOXETINE; FLUNARIZINE; GABAPENTIN; LAMOTRIGINE; LEPTIN; LISINOPRIL; METHYSERGIDE; METOPROLOL; NORTRIPTYLINE; OREXIN; PROPRANOLOL; PROTRIPTYLINE; SEROTONIN; TELMISARTAN; TIMOLOL; TOPIRAMATE; VALPROATE SEMISODIUM; VENLAFAXINE; VERAPAMIL;

BARIATRIC SURGERY; BODY MASS; DIET THERAPY; DISEASE ASSOCIATION; DRIVE; EPISODIC MIGRAINE; EXERCISE; FEEDING; HEADACHE; HUMAN; HYPOTHALAMUS; IDIOPATHIC INTRACRANIAL HYPERTENSION; LOW CARBOHYDRATE DIET; MIGRAINE; OBESITY; PATHOPHYSIOLOGY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; REVIEW; RISK FACTOR; ROUX Y ANASTOMOSIS; TRANSFORMED MIGRAINE; WEIGHT REDUCTION; COMPLICATION; MIGRAINE DISORDERS;

HUMANS; MIGRAINE DISORDERS; OBESITY;

EID: 84895870035     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12297     Document Type: Review

References (90)

1. Chai NC, Scher AI, Moghekar A, Bond DS, Peterlin BL,. Obesity and headache: Part I-A systematic review of the epidemiology of obesity and headache. Headache. 2013. Submitted.
2. Evans RW, Williams MA, Rapoport AM, Peterlin BL,. The association of obesity with episodic and chronic migraine. Headache. 2012; 52: 663-671.
3. Bray GA,. Drug insight: Appetite suppressants. Nat Clin Pract Gastroenterol Hepatol. 2005; 2: 89-95.
4. Coppola A, Diano S,. Hormonal regulation of the arcuate nucleus melanocortin system. Front Biosci. 2007; 12: 3519-3530.
5. Crowley VE, Yeo GS, O'Rahilly S,. Obesity therapy: Altering the energy intake-and-expenditure balance sheet. Nat Rev Drug Discov. 2002; 1: 276-286.
6. Tilg H, Moschen AR,. Adipocytokines: Mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006; 6: 772-783.
7. Blau JN,. Migraine prodromes separated from the aura: Complete migraine. Br Medical J. 1980; 281: 658-660.
8. Denuelle M, Fabre N, Payoux P, Chollet F, Geraud G,. Hypothalamic activation in spontaneous migraine attacks. Headache. 2007; 47: 1418-1426.
9. Peterlin BL, Tietjen GE, Gower BA, et al. Ictal adiponectin levels in episodic migraineurs: A randomized pilot trial. Headache. 2013 Mar; 53: 474-490.
10. Peterlin BL, Rosso AL, Rapoport AM, Scher AI,. Obesity and migraine: The effect of age, gender and adipose tissue distribution. Headache. 2010; 50: 52-62.
11. Peterlin BL, Rapoport AM,. Clinical pharmacology of the serotonin receptor agonist, zolmitriptan. Expert Opin Drug Metab Toxicol. 2007; 3: 899-911.
12. Hamele SPR,. 5-hydroxytryptamine involvement in migraines. In:, Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches, 3rd edn. Philadelphia: Lippincott, Williams and Wilkins Publishers; 2006: 275-280.
13. Nonogaki K, Strack AM, Dallman MF, Tecott LH,. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Medical. 1998; 4: 1152-1156.
14. Blundell JE,. Serotonin and the biology of feeding. Am J Clin Nutr. 1992; 55 (1 Suppl.): 155S-159.
15. Leibowitz SF, Alexander JT,. Hypothalamic serotonin in control of eating behavior, meal size, and body weight. Biol Psychiatry. 1998; 44: 851-864.
16. Halford JC, Harrold JA, Boyland EJ, Lawton CL, Blundell JE,. Serotonergic drugs: Effects on appetite expression and use for the treatment of obesity. Drugs. 2007; 67: 27-55.
17. Bhatt DK, Gupta S, Jansen-Olesen I, Andrews JS, Olesen J,. NXN-188, a selective nNOS inhibitor and a 5-HT1B/1D receptor agonist, inhibits CGRP release in preclinical migraine models. Cephalalgia. 2013; 33: 87-100.
18. Dunlop J, Marquis KL, Lim HK, et al. Pharmacological profile of the 5-HT(2C) receptor agonist WAY-163909; therapeutic potential in multiple indications. CNS Drug Rev. 2006; 12: 167-177. Fall-Winter.
19. Tsujino N, Sakurai T,. Role of orexin in modulating arousal, feeding, and motivation. Front Behav Neurosci. 2013; 7: 28.
20. Chiou LC, Lee HJ, Ho YC, et al. Orexins/hypocretins: Pain regulation and cellular actions. Curr Pharm Des. 2010; 16: 3089-3100.
21. Bingham S, Davey PT, Babbs AJ, et al. Orexin-A, an hypothalamic peptide with analgesic properties. Pain. 2001; 92: 81-90.
22. Heinonen MV, Purhonen AK, Makela KA, Herzig KH,. Functions of orexins in peripheral tissues. Acta Physiol (Oxf). 2008; 192: 471-485.
23. Sakurai T, Amemiya A, Ishii M, et al. Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 1998; 92: 573-585.
24. Mobarakeh JI, Takahashi K, Sakurada S, et al. Enhanced antinociception by intracerebroventricularly administered orexin A in histamine H1 or H2 receptor gene knockout mice. Pain. 2005; 118: 254-262.
25. Feng XM, Mi WL, Xia F, et al. Involvement of spinal orexin A in the electroacupuncture analgesia in a rat model of post-laparotomy pain. BMC Complement Altern Med. 2012; 12: 225. doi: 10.1186/1472-6882-12-225.
26. Suyama H, Kawamoto M, Shiraishi S, Gaus S, Kajiyama S, Yuge O,. Analgesic effect of intrathecal administration of orexin on neuropathic pain in rats. In Vivo. 2004; 18: 119-123.
27. Holland PR, Akerman S, Goadsby PJ,. Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci. 2006; 24: 2825-2833.
28. Holland PR, Akerman S, Goadsby PJ,. Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J Pharmacol Exp Ther. 2005; 315: 1380-1385.
29. Kajiyama S, Kawamoto M, Shiraishi S, et al. Spinal orexin-1 receptors mediate anti-hyperalgesic effects of intrathecally-administered orexins in diabetic neuropathic pain model rats. Brain Res. 2005; 1044: 76-86.
30. Sarchielli P, Rainero I, Coppola F, et al. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: Findings from cerebrospinal fluid. Cephalalgia. 2008; 28: 714-722.
31. Peterlin BL, Bigal ME, Tepper SJ, Urakaze M, Sheftell FD, Rapoport AM,. Migraine and adiponectin: Is there a connection? Cephalalgia. 2007; 27: 435-446.
32. Kos K, Harte AL, da Silva NF, et al. Adiponectin and resistin in human cerebrospinal fluid and expression of adiponectin receptors in the human hypothalamus. J Clin Endocrinol Metab. 2007; 92: 1129-1136.
33. Haugen F, Drevon CA,. Activation of nuclear factor-kappaB by high molecular weight and globular adiponectin. Endocrinology. 2007; 148: 5478-5486.
34. Tsatsanis C, Zacharioudaki V, Androulidaki A, et al. Adiponectin induces TNF-alpha and IL-6 in macrophages and promotes tolerance to itself and other pro-inflammatory stimuli. Biochem Biophys Res Commun. 2005; 335: 1254-1263.
35. Tsao TS, Tomas E, Murrey HE, et al. Role of disulfide bonds in Acrp30/adiponectin structure and signaling specificity. different oligomers activate different signal transduction pathways. J Biol Chem. 2003; 278: 50810-50817.
36. Matsubara M, Maruoka S, Katayose S,. Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol. 2002; 147: 173-180.
37. Bidulescu A, Liu J, Hickson DA, et al. Gender differences in the association of visceral and subcutaneous adiposity with adiponectin in african americans: The Jackson heart study. BMC Cardiovasc Disord. 2013; 13: 2261-13-9.
38. Peterlin BL, Alexander G, Tabby D, Reichenberger E,. Oligomerization state-dependent elevations of adiponectin in chronic daily headache. Neurology. 2008; 70: 1905-1911.
39. Mantzoros CS, Magkos F, Brinkoetter M, et al. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab. 2011; 301: E567-E584.
40. Lin KC, Sagawa N, Yura S, Itoh H, Fujii S,. Simultaneous increases of leptin and gonadotropin-releasing hormone following exogenous estrogen administration in women with normally menstrual cycle. Endocr J. 2005 Aug; 52: 449-454.
41. Kutlu S, Canpolat S, Sandal S, Ozcan M, Sarsilmaz M, Kelestimur H,. Effects of central and peripheral administration of leptin on pain threshold in rats and mice. Neuro Endocrinol Lett. 2003; 24: 193-196.
42. Guldiken B, Guldiken S, Demir M, Turgut N, Tugrul A,. Low leptin levels in migraine: A case control study. Headache. 2008; 48: 1103-1107.
43. Berilgen MS, Bulut S, Gonen M, Tekatas A, Dag E, Mungen B,. Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia. 2005; 25: 1048-1053.
44. Schutt M, Brinkhoff J, Drenckhan M, Lehnert H, Sommer C,. Weight reducing and metabolic effects of topiramate in patients with migraine-an observational study. Exp Clin Endocrinol Diabetes. 2010; 118: 449-452.
45. Bernecker C, Pailer S, Kieslinger P, et al. GLP-2 and leptin are associated with hyperinsulinemia in non-obese female migraineurs. Cephalalgia. 2010; 30: 1366-1374.
46. Otero M, Lago R, Gomez R, et al. Towards a pro-inflammatory and immunomodulatory emerging role of leptin. Rheumatology (Oxford). 2006; 45: 944-950.
47. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr,. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112: 1796-1808.
48. Sarchielli P, Alberti A, Baldi A, et al. Proinflammatory cytokines, adhesion molecules, and lymphocyte integrin expression in the internal jugular blood of migraine patients without aura assessed ictally. Headache. 2006; 46: 200-207.
49. Rozen T, Swidan SZ,. Elevation of CSF tumor necrosis factor alpha levels in new daily persistent headache and treatment refractory chronic migraine. Headache. 2007; 47: 1050-1055.
50. Munno I, Marinaro M, Bassi A, Cassiano MA, Causarano V, Centonze V,. Immunological aspects in migraine: Increase of IL-10 plasma levels during attack. Headache. 2001; 41: 764-767.
51. Bigal ME, Gironda M, Tepper SJ, et al. Headache prevention outcome and body mass index. Cephalalgia. 2006; 26: 445-450.
52. Bond DS, Vithiananthan S, Nash JM, Thomas JG, Wing RR,. Improvement of migraine headaches in severely obese patients after bariatric surgery. Neurology. 2011; 76: 1135-1138.
53. Novack V, Fuchs L, Lantsberg L, et al. Changes in headache frequency in premenopausal obese women with migraine after bariatric surgery: A case series. Cephalalgia. 2011; 31: 1336-1342.
54. Gunay Y, Jamal M, Capper A, Eid A, Heitshusen D, Samuel I,. Roux-en-Y gastric bypass achieves substantial resolution of migraine headache in the severely obese: 9-year experience in 81 patients. Surg Obes Relat Dis. 2013; 9: 55-62.
55. Thomas JG, Bond DS, Phelan S, Hill JO, Wing RR,. 10-year weight loss maintenance in the national weight control registry (NWCR). Am J Prev Medical. 2013; in press.
56. Look AHEAD Research Group, Wing RR, Bolin P, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Medical. 2013; 369: 145-154.
57. Adams TD, Davidson LE, Litwin SE, et al. Health benefits of gastric bypass surgery after 6 years. JAMA. 2012; 308: 1122-1131.
58. Health Quality Ontario. Bariatric surgery: An evidence-based analysis. Ont Health Technol Assess Ser. 2005; 5: 1-148.
59. Egan RJ, Meredith HE, Coulston JE, Bennetto L, Morgan JD, Norton SA,. The effects of laparoscopic adjustable gastric banding on idiopathic intracranial hypertension. Obes Surg. 2011; 21: 161-166.
60. Sugerman HJ, Felton WL 3rd, Sismanis A, Kellum JM, DeMaria EJ, Sugerman EL,. Gastric surgery for pseudotumor cerebri associated with severe obesity. Ann Surg. 1999; 229: 634-640, discussion 640-2.
61. Wober C, Brannath W, Schmidt K, et al. PAMINA Study Group. Prospective analysis of factors related to migraine attacks: The PAMINA study. Cephalalgia. 2007; 27: 304-314.
62. Robberstad L, Dyb G, Hagen K, Stovner LJ, Holmen TL, Zwart JA,. An unfavorable lifestyle and recurrent headaches among adolescents: The HUNT study. Neurology. 2010; 75: 712-717.
63. Haque B, Rahman KM, Hoque A, et al. Precipitating and relieving factors of migraine versus tension type headache. BMC Neurol. 2012; 12: 2377-12-82.
64. Lemstra M, Stewart B, Olszynski WP,. Effectiveness of multidisciplinary intervention in the treatment of migraine: A randomized clinical trial. Headache. 2002; 42: 845-854.
65. Koseoglu E, Akboyraz A, Soyuer A, Ersoy AO,. Aerobic exercise and plasma beta endorphin levels in patients with migrainous headache without aura. Cephalalgia. 2003; 23: 972-976.
66. Narin SO, Pinar L, Erbas D, Ozturk V, Idiman F,. The effects of exercise and exercise-related changes in blood nitric oxide level on migraine headache. Clin Rehabil. 2003; 17: 624-630.
67. Dittrich SM, Gunther V, Franz G, Burtscher M, Holzner B, Kopp M,. Aerobic exercise with relaxation: Influence on pain and psychological well-being in female migraine patients. Clin J Sport Medical. 2008; 18: 363-365.
68. Varkey E, Cider A, Carlsson J, Linde M,. A study to evaluate the feasibility of an aerobic exercise program in patients with migraine. Headache. 2009; 49: 563-570.
69. Darabaneanu S, Overath CH, Rubin D, et al. Aerobic exercise as a therapy option for migraine: A pilot study. Int J Sports Medical. 2011 32: 455-460.
70. Verrotti A, Agostinelli S, D'Egidio C, et al. Impact of a weight loss program on migraine in obese adolescents. Eur J Neurol. 2013; 20: 394-397.
71. Rockett FC, de Oliveira VR, Castro K, Chaves ML, Perla Ada S, Perry ID,. Dietary aspects of migraine trigger factors. Nutr Rev. 2012; 70: 337-356.
72. Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJ,. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: A randomized trial. JAMA. 2005; 293: 43-53.
73. Bic Z, Blix GG, Hopp HP, Leslie FM, Schell MJ,. The influence of a low-fat diet on incidence and severity of migraine headaches. J Womens Health Gend Based Med. 1999; 8: 623-630.
74. Hasselmark L, Malmgren R, Hannerz J,. Effect of a carbohydrate-rich diet, low in protein-tryptophan, in classic and common migraine. Cephalalgia. 1987; 7: 87-92.
75. Maggioni F, Margoni M, Zanchin G,. Ketogenic diet in migraine treatment: A brief but ancient history. Cephalalgia. 2011; 31: 1150-1151.
76. Kossoff EH, Huffman J, Turner Z, Gladstein J,. Use of the modified Atkins diet for adolescents with chronic daily headache. Cephalalgia. 2010; 30: 1014-1016.
77. Verrotti A, Agostinelli S, D'Egidio C, et al. Impact of a weight loss program on migraine in obese adolescents. Eur J Neurol. 2013; 20: 394-397.
78. Bond DS, O'Leary KC, Thomas JG, et al. Can weight loss improve migraine headaches in obese women? Rationale and design of the women's health and migraine (WHAM) randomized controlled trial. Contemp Clin Trials. 2013; 35: 133-144.
79. Sinclair AJ, Burdon MA, Nightingale PG, et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: Prospective cohort study. BMJ. 2010; 341: c2701.
80. Newborg B,. Pseudotumor cerebri treated by rice reduction diet. Arch Intern Medical. 1974; 133: 802-807.
81. Kupersmith MJ, Gamell L, Turbin R, Peck V, Spiegel P, Wall M,. Effects of weight loss on the course of idiopathic intracranial hypertension in women. Neurology. 1998; 50: 1094-1098.
82. Wong R, Madill SA, Pandey P, Riordan-Eva P,. Idiopathic intracranial hypertension: The association between weight loss and the requirement for systemic treatment. BMC Ophthalmol. 2007; 7: 15.
83. Johnson LN, Krohel GB, Madsen RW, March GA Jr,. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology. 1998; 105: 2313-2317.
84. Glueck CJ, Golnik KC, Aregawi D, Goldenberg N, Sieve L, Wang P,. Changes in weight, papilledema, headache, visual field, and life status in response to diet and metformin in women with idiopathic intracranial hypertension with and without concurrent polycystic ovary syndrome or hyperinsulinemia. Transl Res. 2006; 148: 215-222.
85. Taylor FR,. Weight change associated with the use of migraine-preventive medications. Clin Ther. 2008; 30: 1069-1080.
86. Peterlin BL, Calhoun AH, Siegel S, Mathew NT,. Rational combination therapy in refractory migraine. Headache. 2008; 48: 805-819.
87. Kowacs PA, Piovesan EJ, Tepper SJ,. Rejection and acceptance of possible side effects of migraine prophylactic drugs. Headache. 2009; 49: 1022-1027.
88. Maggioni F, Ruffatti S, Dainese F, Mainardi F, Zanchin G,. Weight variations in the prophylactic therapy of primary headaches: 6-month follow-up. J Headache Pain. 2005; 6: 322-324.
89. Dodick DW, Freitag F, Banks J, et al. Topiramate versus amitriptyline in migraine prevention: A 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs. Clin Ther. 2009; 31: 542-559.
90. Alberici A, Borroni B, Manelli F, et al. Topiramate weight loss in migraine patients. J Neurol Sci. 2009; 278: 64-65.